Should India Reclassify Paracetamol? The Hepatotoxicity Debate

The Ubiquity Problem

Paracetamol (acetaminophen) is India's most consumed analgesic, available without prescription at every pharmacy, grocery store, and pan shop. Its perceived safety has made it the default remedy for pain and fever. But this perception is dangerously incomplete.

Rising Hepatotoxicity Cases

Data from major Indian liver centers shows a concerning trend: paracetamol-related acute liver failure cases have increased 3-fold over the past decade. Many cases involve unintentional overdose — patients taking multiple paracetamol-containing products simultaneously without realizing the cumulative dose.

The Combination Product Issue

India's market is flooded with combination products containing paracetamol: cough syrups, flu tablets, migraine formulations, and muscle relaxant combinations. A patient taking a "cold tablet," a "headache tablet," and a "body pain tablet" might unknowingly consume 3-4 grams of paracetamol in a few hours.

Arguments for Reclassification

• Mandatory pack size limits (as in the UK)
• Clear unit-dose labeling with maximum daily dose warnings
• Pharmacist counseling requirement for purchases
• Restriction on combination products containing paracetamol

Arguments Against

• Paracetamol is essential for millions who cannot access or afford NSAIDs
• Restricting access may push patients toward more dangerous alternatives
• Enforcement challenges in India's vast informal pharmacy network

A Middle Path

Rather than full reclassification, India could implement targeted measures: mandatory patient information leaflets, maximum pack sizes for non-pharmacy sales, and public awareness campaigns about paracetamol's hepatotoxic potential at doses above 4g/day.